Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen

Cancer Research

Volumn 56, Issue 16, 1996, Pages 3704-3710

  Nuwaysir, Emile F ^a   Daggett, Daniel A ^a   Jordan, V Craig ^b   Pitot, Henry C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ANDROSTENEDIONE; ANTIESTROGEN; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; ISOENZYME; MESSENGER RNA; SULFOTRANSFERASE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; ENZYME REPRESSION; ENZYME SUBUNIT; FEEDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER CYTOSOL; MALE; NONHUMAN; NORTHERN BLOTTING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA ANALYSIS;

ANIMALS; BASE SEQUENCE; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LIVER; MALE; MOLECULAR SEQUENCE DATA; RATS; RATS, INBRED F344; SULFURTRANSFERASES; TAMOXIFEN;

EID: 0029783146     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Jordan, V. C. Long-term tamoxifen therapy for breast cancer. In: V. T. DeVita, S. Hellman, and S Rosenberg (eds.), Important Advances in Oncology, pp 179-192. Philadelphia. J. B. Lippincott Co., 1989.
2. Jordan, V. C., and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocrinol. Rev., 11: 578-610, 1990.
3. Legha, S., and Carter, S Antiestrogens in the treatment of breast cancer. Cancer Treat. Rev , 3: 205-216, 1976.
4. Rutqvist, L. E., Cedermark, B , Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J , Hjalmar, M., Rotstein, S., Perbeck, L., and Ringborg, U Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl. Cancer Inst., 83: 1299-1306, 1991.
5. Powles, T. J., Jones, A. L . Ashley, S. E , O'Brien, M., Tidy, V. A , Treleavan, J., Cosgrove, D., Nash, A. G , Sacks, N., Baum, M., McKinna, J A , and Davey, J B. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat., 31: 73-82, 1994.
6. Nayfield, S. G., Karp, J. E., Ford, L. G , Dorr, F. A , and Kramer, B. S. Potential role of tamoxifen in prevention of breast cancer J Natl. Cancer Inst., 83: 1450-1459, 1991.
7. Greaves, P., Goonetillek, R , Nunn, G., Topham, J., and Orton, T Two-year carcinogenicity study in Alderley Park Wistar-derived rats. Cancer Res., 53: 3919-3924, 1993.
8. Hard, G. C., Iatropoulos, M. J , Jordan, K , Radi, L., Kaltenberg, O. P., Imondi, A R., and Williams, G M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53: 4534-4541, 1993
9. Hirsimaki, P , Hirsimaki, Y , Nieminen, L., and Payne, P. J. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch Toxicol., 67: 49-54, 1993
10. Williams, G. M , Iatropoulos, M J., Djordjevic, M. V , and Kaltenberg, O P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat Carcinogenesis (Lond.), 14: 315-317, 1993.
11. Jordan, V. C Tamoxifen and tumorigenicity: a predictable concern. J. Natl. Cancer Inst., 87: 623-626, 1995.
12. Fornander, T., Cedermark, B, Mattsson, A., Skoog, L., Theve, T., Askergren, J., Rutquist, L. E., Silfversward, C , Somell, A., Wilking, N., and Hjalmar, M L. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1: 117-120, 1989.
13. Fisher, B., Constantino, J. P , Redmond, C. K., Fisher, E. R., Wickerham, D L., Cronin, W. M., and Other NSABP Contributors Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst , 86: 527-537, 1994.
14. Mani, C , and Kupfer, D. Cytochrome P450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res , 51: 6052-6058, 1991
15. Potter, G. A., McCague, R., and Jarman, M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis (Lond.), 15: 439-442, 1994
16. Han, X , and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen Cancer Res , 52: 1360-1363, 1992.
17. White, I N. H., de Matteis, F., Davies, A., Smith, L. L , Crofton-Sleigh, C., Venitt, S , Hewer, A , and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis (Lond), 13: 2197-2203, 1992.
18. Pathak, D. P , and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis (Lond.), 15 529-532, 1994.
19. Pongracz, K., Pathak, D. N., Nakamura, T , Burlingame, A. L., and Bodell, W. J Activation of tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res , 55: 3012-3015, 1995.
20. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation. Carcinogenesis (Lond.), 16: 1299-1304, 1995.
21. Sargent, L. M , Dragan, Y. P , Bahnub, N., Wiley, J. E., Sattler, C A , Schroeder, P., Sattler, G. L., Jordan, V. C., and Pitot, H C. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats Cancer Res , 54: 3357-3360, 1994
22. Styles, J A , Davies, A., Lim, C. K , de Matteis, F., Stanley, L A., White, I. N. H., Yuan, Z-X., and Smith, L. L. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis (Lond), 15: 5-9, 1994
23. Davies, A M , Martin, E A., Jones, R M , Lim, C K., Smith, L L , and White, I. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis (Lond.), 16: 539-545, 1995
24. Mani, C., Pearce, R , Parkinson, A., and Kupfer, D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis (Lond), 15: 2715-2720, 1994.
25. Turner, M J, Fields, C E , and Everman, D B. Evidence for superoxide formation during hepatic metabolism of tamoxifen. Biochem. Pharmacol , 41: 1701-1705, 1991
26. Phillips, D H., Carmichael, P L , Hewer, A., Cole, K J., and Poon, G K α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54: 5518-5522, 1994.
27. Poon, G K., Walter, B. Lonning, P E., Horton, M. N., and McCague, R Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and in patients on long-term therapy for breast cancer Drug Metab Dispos., 23, 377-382, 1995.
28. Jarman, M., Poon, G K., Rowlands, M. G , Grimshaw, R. M., Horton, M. N., Potter, G. A., and McCague, R The deuterium isotope effect for the α-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of [D5-ethyl]-tamoxifen. Carcinogenesis (Lond.), 16: 683-688, 1995
29. Phillips, D H , Potter, G A., Horton, M N., Hewer, A , Crofton-Sleigh, C., Jarman, M , and Venitt, S. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (Lond), 15: 1487-1492, 1994
30. Osborne, M. R , Hewer, A., Hardcastle, I. R., Carmichael, P L , and Phillips, D. H Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res , 56: 66-71, 1996
31. 32P-postlabelling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis (Lond.), 15: 2087-2094, 1994.
32. Randerath, K., Bi, J., Mabon, N., Sriram, P., and Moorthy, B. Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol Carcinogenesis (Lond.), 15: 797-800, 1994.
33. McCague, R., Parr, I. B., Leclercq, G., Leung, O., and Jarman, M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem. Pharmacol., 39: 1459-1465, 1990.
34. Mannervik, B., and Danielson, U. H Glutathione-S-transferases: structure and catalytic activity. Crit. Rev. Biochem Mol. Biol , 23: 283-337, 1988
35. Beetstra, J. B., van Engelen, J., Karels, P., van der Hoek, H , de Jong, M , Docter, R., Krenning, E. P., Hennemann. G , Brouwer, A., and Visser, T. J. Thyroxine and 3,3′,5-triiodothyronine are glucuronidated in rat liver by different uridine diphosophate-glucuronyltransferases Endocrinology, 128: 741-746, 1991.
36. Barter, R , and Klassen, C D Rat liver microsomal UDP-glucuronosyltransferase activity toward thyroxine: characterization, induction, and form specificity. Toxicol. Appl Pharmacol., 115: 261-267, 1992.
37. Visser, T. J., Kaptein, E., van Raaij, J , Joe, C. T. T., Ebner, T., and Burchell, B. Multiple UDP-glucuronyltransferases for the glucuronidation of thyroid hormone with preference for 3,3′,5′-triiodothyronine (reverse T3). FEBS Lett., 315: 65-68, 1993.
38. Visser, T. J. Role of sulfation in thyroid hormone metabolism. Chem.-Biol Interact., 92: 293-303, 1994.
39. Chatterjee, B., Song, C. S., Kim, J M., and Roy, A. K. Androgen and estrogen sulfotransferases of the rat liver. physiological function, molecular cloning and in vitro expression. Chem -Biol Interact., 92: 273-279, 1994.
40. Labrie, Y., Couet, J., Simard, J., and Labrie, F. Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver. Endocrinology, 134: 1693-1699, 1994.
41. Nagata, K., Ozawa, S., Miyata, M., Shimada, M., Gong, D , Yamazoe, Y , and Kato, R. Isolation ad expression of a cDNA encoding a male-specific rat sulfotransferase that catalyzes activation of N-hydroxy-2-acetylaminofluorene. J. Biol. Chem., 268: 24720-24725, 1993.
42. Leblanc, G. A , Sundseth, S. S., Weber, G. F., and Waxman, D. J. Platinum anticancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid metabolism in male and female rats. Cancer Res., 52, 540-547, 1992.
43. Srivastava, P K , and Waxman, D J. Sex-dependent expression and growth hormone regulation of class α and class μ glutethione S-transferase mRNAs in adult rat liver Biochem J , 294, 159-165, 1993.
44. Nuwaysir, E F , Dragan, Y. P , Jefcoate, C. R , Jordan, V C , and Pitot, H. C Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver Cancer Res., 55: 1780-1786, 1995.
45. White, I N H, Davies, A., Smith, L L , Dawson, S , and de Matteis, F Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice Biochem. Pharmacol, 45: 21-30, 1993.
46. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
47. Chomczynski, P., and Sacchi, N Single-step method of RNA isolation by acid guanidinium thiocyanante-phenol-chloroform extraction Anal. Biochem., 162: 156-159, 1987.
48. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed 2, p 12.20. Cold Spring Harbor, NY. Cold Spring Harbor Laboratory Press, 1989.
49. Waxman, D J., Sundseth, S. S., Srivastava, P. K., and Lapenson, D P. Gene-specific oligonucleotide probes for α, μ, π, and microsomal rat glutathione S-transferases. analysis of liver transferase expression and its modulation by hepatic enzyme inducer and platinum anticancer drugs. Cancer Res., 52, 5797-5802, 1992.
50. 5-3-detosteroid isomerase and the glutathione S-transferases of the liver. Proc. Natl. Acad. Sci. USA, 74: 158-162, 1977.
51. Habig, W. H., and Jakoby, W. B. Assays for differentiation of glutathione S-transferases. Methods Enzymol., 77: 398-405, 1981.
52. Johnson, J. A., Finn, K A , and Siegel, F L. Tissue distribution of enzymatic methylation of glutathione S-transferase and its effects on catalytic activity. Biochem J., 282 279-289, 1992.
53. Hayes, J. D. Selective elution of rodent glutathione S-transferase and glyoxalase I from S-hexylglutathione-sepharose affinity matrix. Biochem. J , 255: 913-922, 1988.
54. Johnson, J. A., Hayward, J. J , Kornguth, S. E., and Siegel, F. L. Effects of hyperbilirubinaemia on glutathione S-transferase isoenzymes in cerebellar cortex of the Gunn rat. Biochem. J , 291: 453-461, 1993.
55. Hayes, J. D, and Pulford, D. J The glutathione-S-transferase supergene family: regulation of GST* and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev Biochem Mol. Biol , 30 445-600, 1995.
56. Mackenzie, P I Rat liver UDP-glucuronosyltransferase. Sequence and expression of a cDNA encoding a phenobarbital-inducible form. J. Biol. Chem., 261: 6119-6125, 1986
57. Jacolot, F., Simon, I., Dreano, Y , Beaune, P , Riche, C , and Berthou, F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes Biochem. Pharmacol., 41: 1911-1919, 1991.
58. Mani, C., Gelboin H. V., Park, S. S., Pearce, R , Parkinson, A., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. 1. Cytochrome P450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos , 21: 645-656, 1993
59. Watkins, P. B., Wrighton, S A., Maurel, P. Scheutz, E. G., Mendez-Picon, G , Parker, G A., and Guzelian, P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci USA, 82: 6310-6314, 1985.
60. Larsen, M. C , Brake, P. B., Parmar, D , and Jefcoate, C R. The induction of five rat hepatic P450 cytochromes by phenobarbital and similarly acting compounds is regulated by a sexually dimorphic, dietary-dependent endocrine factor that is highly strain specific. Arch. Biochem. Biophys., 315: 24-34, 1994
61. Ahotupa, M , Hirsimaki, P., Parssinen, R., and Manytla, E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis (Lond.), 15 863-868, 1994.
62. Lavoie, L., Tremblay, A , and Mirault, M E Distinct oxidoresistance phenotype of human T47D cells transfected by rat glutathione S-transferase Yc Expression vectors. J. Biol Chem., 267: 3632-3636, 1992
63. Berhane, K. Widersten, M., Engstrom, A., Kozarich, J W., and Mannervik, B. Detoxication of base propenals and other α,β-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc. Natl. Acad. Sci USA, 91: 1480-1484, 1994
64. Leblanc, G. A , and Waxman, D J. Feminization of rat hepatic P450 expression by cisplatin. J. Biol. Chem., 263: 15732-15739, 1988
65. Jansson, J., and Frohman, L A Differential effects of neonatal and adult androgen exposure on the growth hormone secretory pattern in male rats. Endocrinology, 120 1551-1557, 1987.
66. PB1 (IIC6) gene expression Mol. Pharmacol., 38 192-197, 1990.
67. Tannenbaum, G. S., Gurd, W., Lapointe, M , and Pollak, M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130: 3395-3401, 1992